HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

NCT05311319 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
70
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fudan University